Researchers led by the Dana-Farber Cancer Institute's William Hahn report in Cancer Discovery that the gene CRKL is amplified and over-expressed in non-small cell lung cancers with 22q11.21 amplifications. CRKL. Further, the "over expression of CRKL induces cell transformation and resistance to epidermal growth factor receptor inhibitor treatment and [suggests] that therapeutic interventions targeting CRKL may confer a clinical benefit in a defined subset of NSCLCs," the authors write.
Johns Hopkins University researchers found that combining epigenetic therapy with chemotherapy led to "durable responses in patients with solid tumors." However, the authors add that "objective responses to this therapy in this heavily pretreated population occurred in only 4 [percent] of the patients, but the antitumor responses that were observed were impressive."